Epclusa vs Mavyret
Side-by-side cost comparison based on Medicare Part D data
Epclusa
Sofosbuvir/Velpatasvir
Manufactured by Gilead
Mavyret
Glecaprevir/Pibrentasvir
Manufactured by AbbVie
Epclusa costs 0% less per claim than Mavyret ($26,143.00 vs $26,250.00). A generic version of Epclusa is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Epclusa | Mavyret |
|---|---|---|
| Avg Cost Per Claim | $26,143.00 | $26,250.00 |
| Total Medicare Spending | $1.1B | $945.0M |
| Total Beneficiaries | 10,000 | 9,000 |
| Total Claims | 42,000 | 36,000 |
| Annual Cost/Patient | $109,800.00 | $105,000.00 |
| Year-over-Year Change | -15.7% | -21.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Gilead | AbbVie |
| Condition | Hepatitis C | Hepatitis C |
| Generic Name | Sofosbuvir/Velpatasvir | Glecaprevir/Pibrentasvir |
Epclusa vs Mavyret: What the Data Shows
Epclusa (Sofosbuvir/Velpatasvir) and Mavyret (Glecaprevir/Pibrentasvir) are both used to treat hepatitis c. Based on Medicare Part D data, Epclusa costs $26,143.00 per claim, which is 0% less than Mavyret at $26,250.00 per claim.
Medicare spent $1.1B on Epclusa and $945.0M on Mavyret. In terms of patient reach, Epclusa serves more beneficiaries (10,000 vs 9,000).
Year-over-year spending changed -15.7% for Epclusa and -21.4% for Mavyret.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Epclusa is cheaper at $26,143.00 per claim, compared to $26,250.00 for Mavyret. That makes Epclusa about 0% less expensive per claim based on Medicare Part D data.
Yes, both Epclusa and Mavyret are used to treat hepatitis c. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Sofosbuvir/Velpatasvir and generic Glecaprevir/Pibrentasvir can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.1B on Epclusa covering 10,000 beneficiaries, and $945.0M on Mavyret covering 9,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.